Please assess the completion status of the following clinical trial:

Trial Title: Study of Nitazoxanide Tablets in the Treatment of Mild to Moderate Active Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years.~* Diagnosis of Crohn's disease with colonic or perianal involvement confirmed by endoscopic, histologic and/or radiologic data.~* CDAI score ≥200 and ≤400.~Exclusion Criteria:~* Subjects known to have stool positive for Clostridium difficile toxin A or B, bacterial enteric pathogens, rotavirus, Cryptosporidium species (spp.), and/or ova/parasites.~* Evidence of bowel obstruction.~* Females that are pregnant, breast-feeding or not using birth control and are sexually active.~* Serious systemic disorders incompatible with the study.~* History of hypersensitivity to nitazoxanide or any inactive ingredient in the formulation.~* Uncontrolled gastro-intestinal bleeding.~* Evidence of intestinal abscess, non-perianal fistula or stricture.~* Patients who have received antibiotics in the past 7 days.~* Patients receiving \>20 mg of prednisone, or its equivalent.~* Patients receiving Anucort-HC or rectal steroids.~* Patients receiving immunosuppressive therapy that has not been stabilized.~* Patients who have received TNF-alpha inhibitor treatments such as infliximab or other biological agents within three months prior to start of treatment.~* Patients with Crohn's disease confined to the esophagus, stomach and small bowel.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): One nitazoxanide 500 mg tablet twice daily for 28 days
- 2 (Type: PLACEBO_COMPARATOR): One placebo tablet twice daily for 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).